MX2009002686A - Derivados de acetamida de quinazolinona e isoquinolinona. - Google Patents

Derivados de acetamida de quinazolinona e isoquinolinona.

Info

Publication number
MX2009002686A
MX2009002686A MX2009002686A MX2009002686A MX2009002686A MX 2009002686 A MX2009002686 A MX 2009002686A MX 2009002686 A MX2009002686 A MX 2009002686A MX 2009002686 A MX2009002686 A MX 2009002686A MX 2009002686 A MX2009002686 A MX 2009002686A
Authority
MX
Mexico
Prior art keywords
optionally substituted
6alkyl
halogen
3alkyl
hydroxy
Prior art date
Application number
MX2009002686A
Other languages
English (en)
Inventor
Duncan Robert Mcarthur
Jeffrey Letourneau
Koc-Kan Ho
Michael Ohlmeyer
Patrick Jokiel
Paul David Ratcliffe
Elizabeth Napier
Jeremiah Fiona
Schulz Jurgen
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of MX2009002686A publication Critical patent/MX2009002686A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un derivado de quinazolinona o isoquinolinona de la fórmula I, en donde R1 es C1-6alquilo, C3-6clicloalquilo, C3-6cicloalquilC1-3alquilo, C2-6alquenilo, C2-6alquinilo, siendo los C1-6alquilo, C3-6cicloalquilo y C3-6cicloalquilC1-3alquilo opcionalmente sustituidos con hidroxi, C1-6alquiloxi, ciano o uno o más halógenos; R2 es C6-10arilo opcionalmente substituido con de uno a tres sustituyentes seleccionados de halógeno, hidroxi, ciano, C1-6alquilo, C3-6cicloalquilo, C1-6alquiloxi, y C3-6cicloalquiloxi, siendo los C1-6alquilo, C3-6cicloalquilo, C1-6alquiloxi y C3-6Cicloalquiloxi, opcionalmente substituidos con uno o más halógenos; o R2 es un sistema de anillo de heteroarilo de 5 a 10 miembros que comprende un heteroátomo seleccionado de N,O y S, y opcionalmente substituido con un sustituyente seleccionado de metilo, C1-6alquiloxi y halógeno; o R2 es C4-7cicloalquilo; R3 es un sustituyente opcional seleccionado de C1-6alquilo, C1-6alquiloxi y halógeno, siendo el C1-6alquilo y C1-6alquiloxi opcionalmente sustituido con uno o más halógenos; R4 es un grupo localizado en la posición 6- ó 7- del anillo de quinazolinona o isoquinolinona que tiene la fórmula II, en donde R5 junto con uno de R6 forma un anillo heterocíclico saturado o insaturado de 4 a 8 miembros que comprende opcionalmente una porción heteroaromática adicional seleccionada de O, S y NR9, siendo sustituido el anillo heterocíclico con uno o dos sustituyentes seleccionados de metilo, halógeno, hidroxi y oxo o R5 junto con uno de R7 y R8 forma un anillo heterocíclico de 6 a 8 miembros opcionalmente sustituido de uno a dos sustituyentes seleccionados de metilo, halógeno, hidroxi y oxo; cada R6 es independientemente H, halógeno o C1-4alquilo opcionalmente sustituido con halógeno o SO2CH3 o uno de R6 junto con R5 forma un anillo heterocíclico saturado o insaturado de 4 a 8 miembros que comprende opcionalmente una porción heteroaromática adicional seleccionada de O, S y NR9, siendo el anillo heterocíclico opcionalmente sustituido con uno o dos sustituyentes seleccionados de metilo, halógeno, hidroxi y oxo; R7 y R8 son independientemente H, C1-6alquilo, C3-6cilcoalquilo, C3-6cicloalquilC1-3alquilo, cianoC1-3alquilo, C6-10arilo, C6-10arilC1-3alquilo, C1-3alquiloxiC1-3alquilo ó C1-6acilo siendo el C1-6alquilo, C1-3cicloalquilo y C3-6cicloalquilC1-3alquilo opcionalmente sustituido con hidroxi, 1 o más halógenos o diC1-2alquilamino; o R7 y R8 junto con el nitrógeno al cual se enlazan forman un anillo heterocíclico saturado o insaturado de 4 a 8 miembros que comprende opcionalmente una porción heteroatómica adicional seleccionada de O, S y NR10, siendo el anillo heterocíclico opcionalmente substituido con uno o dos sustituyentes seleccionados de C1-6alquilo, halógeno, hidorxi.
MX2009002686A 2006-09-11 2007-09-10 Derivados de acetamida de quinazolinona e isoquinolinona. MX2009002686A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84371806P 2006-09-11 2006-09-11
PCT/US2007/078022 WO2008033764A2 (en) 2006-09-11 2007-09-10 Quinazolinone and isoquinolinone acetamide derivatives

Publications (1)

Publication Number Publication Date
MX2009002686A true MX2009002686A (es) 2009-10-13

Family

ID=39184483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002686A MX2009002686A (es) 2006-09-11 2007-09-10 Derivados de acetamida de quinazolinona e isoquinolinona.

Country Status (20)

Country Link
US (1) US7820649B2 (es)
EP (1) EP2069315B1 (es)
JP (1) JP5256202B2 (es)
KR (1) KR20090107994A (es)
CN (1) CN101600698B (es)
AR (1) AR062731A1 (es)
AT (1) ATE523500T1 (es)
AU (1) AU2007296634B2 (es)
CA (1) CA2663161C (es)
CL (1) CL2007002635A1 (es)
CO (1) CO6160322A2 (es)
EC (1) ECSP099177A (es)
IL (1) IL197530A0 (es)
MX (1) MX2009002686A (es)
NO (1) NO20091012L (es)
NZ (1) NZ575426A (es)
PE (1) PE20080841A1 (es)
RU (1) RU2009113612A (es)
TW (1) TW200827352A (es)
WO (1) WO2008033764A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010229035A (ja) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
WO2009130231A1 (en) * 2008-04-24 2009-10-29 Glaxo Group Limited Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists
JP5369721B2 (ja) * 2009-01-30 2013-12-18 大正製薬株式会社 ピリドピリミジン−４−オン誘導体
RU2012119488A (ru) 2009-10-13 2013-11-20 Мсд Осс Б.В. Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором
NZ608729A (en) 2010-10-01 2014-08-29 Taisho Pharmaceutical Co Ltd 1,2,4-triazolone derivative
KR101998442B1 (ko) 2011-10-27 2019-07-09 다이쇼 세이야꾸 가부시끼가이샤 아졸 유도체
AU2013241076A1 (en) * 2012-03-30 2014-10-09 Taisho Pharmaceutical Co., Ltd. Fused azole derivative
RS55717B1 (sr) 2012-06-13 2017-07-31 Hoffmann La Roche Novi diazaspirocikloalkan i azaspirocikloalkan
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
KR20160087900A (ko) 2013-11-26 2016-07-22 에프. 호프만-라 로슈 아게 신규한 옥타하이드로-사이클로부타[1,2-c；3,4-c'']다이피롤-2-일
EP3122750B1 (en) 2014-03-26 2019-09-04 F.Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
PE20161223A1 (es) 2014-03-26 2016-11-12 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa)
CN106573882B (zh) * 2014-08-04 2020-09-01 桑多斯股份公司 制备苏沃雷生的合成途径
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
RU2746481C1 (ru) 2015-09-04 2021-04-14 Ф. Хоффманн-Ля Рош Аг Феноксиметильные производные
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
PE20180451A1 (es) 2015-09-24 2018-03-05 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de atx
WO2017050791A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
RS60834B1 (sr) 2015-12-09 2020-10-30 Cadent Therapeutics Inc Modulatori heteroaromatskog nmda receptora i njihove upotrebe
EP3386990B1 (en) 2015-12-09 2023-04-19 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
JP7332472B2 (ja) 2016-12-22 2023-08-23 ノバルティス アーゲー Ｎｍｄａ受容体モジュレーターおよびその使用
KR20190129924A (ko) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
EA202190431A1 (ru) 2018-08-03 2021-06-11 Кэйдент Терапьютикс, Инк. Гетероароматические модуляторы nmda рецептора и их применение
CN111100063B (zh) * 2018-10-25 2022-05-17 南京药石科技股份有限公司 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2506767A1 (fr) * 1981-05-26 1982-12-03 Synthelabo Derives heterocycliques d'amidoximes, leur preparation et leur application en therapeutique
CA2288140C (en) 1997-04-25 2007-04-03 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
IL139199A (en) 1999-11-02 2006-10-31 Nihon Nohyaku Co Ltd Derivatives of aminoquinazolinone (thion) or their salts, their intermediates, pesticides and method of use
FR2804114B1 (fr) * 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2842527B1 (fr) * 2002-07-19 2005-01-28 Sanofi Synthelabo Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique
AU2005205016B2 (en) * 2004-01-16 2010-07-15 F. Hoffmann-La Roche Ag 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1H-quinazolin-2-one derivatives and the respective 1H-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(D) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-HT) for the treatment of diseases of the central nervous system
EP1757594A4 (en) * 2004-05-31 2007-12-12 Banyu Pharma Co Ltd quinazoline derivative
WO2006012577A2 (en) * 2004-07-22 2006-02-02 Bayer Pharmaceuticals Corporation Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
CN101528703B (zh) * 2006-09-11 2011-09-07 欧加农股份有限公司 2-（1-氧代-1h-异喹啉-2-基）乙酰胺衍生物

Also Published As

Publication number Publication date
EP2069315A4 (en) 2010-11-03
CO6160322A2 (es) 2010-05-20
WO2008033764A2 (en) 2008-03-20
RU2009113612A (ru) 2010-10-20
ECSP099177A (es) 2009-06-30
CL2007002635A1 (es) 2009-10-23
EP2069315B1 (en) 2011-09-07
EP2069315A2 (en) 2009-06-17
JP5256202B2 (ja) 2013-08-07
AU2007296634B2 (en) 2012-09-20
WO2008033764A3 (en) 2008-12-18
JP2010502746A (ja) 2010-01-28
KR20090107994A (ko) 2009-10-14
AU2007296634A1 (en) 2008-03-20
CA2663161A1 (en) 2008-03-20
NO20091012L (no) 2009-03-26
CA2663161C (en) 2014-10-28
TW200827352A (en) 2008-07-01
US7820649B2 (en) 2010-10-26
CN101600698B (zh) 2012-01-11
CN101600698A (zh) 2009-12-09
ATE523500T1 (de) 2011-09-15
NZ575426A (en) 2010-09-30
PE20080841A1 (es) 2008-06-14
AR062731A1 (es) 2008-11-26
US20080090802A1 (en) 2008-04-17
IL197530A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
MX2009002686A (es) Derivados de acetamida de quinazolinona e isoquinolinona.
CO6150164A2 (es) Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor
CR8755A (es) Derivado de quinolina fusionada y uso del mismo
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR074435A1 (es) Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.
RS52397B (en) PYRIDO / 2,1-A / ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS
AR077507A1 (es) Derivados de naftiridina-1-ona y composiciones farmaceuticas que los comprenden como inhibidores de cinasa syk
AR087919A1 (es) Heterociclos biciclicos como inhibidores de irak4
TW200643015A (en) 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
AR060875A1 (es) Derivados de 2-piridona como inhibidores de la neutrofilo elastasa humana
CO6321239A2 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
DOP2010000046A (es) Compuestos de biciclolactama sustituida
ATE556058T1 (de) 1-(2h)-isochinolonderivat
AR053436A1 (es) Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
AR060874A1 (es) Compuestos derivados de 2-piperazinona
AR062125A1 (es) Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos
AR057209A1 (es) Compuestos para el tratamiento de trastornos inflamatorios y enfermedades microbianas
AR049894A1 (es) Derivados de prolina y sus usos como inhibodores de la enzima dipeptidilpeptidasa-iv
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
AR068098A1 (es) Derivados de ciclopentandiona como herbicidas
MX2009002685A (es) Derivados de acetamida de (2- (1-oxo-1h-isoquinolin-2-il).
EA201070839A1 (ru) Новые производные ацилцианопирролидинов

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: N.V. ORGANON.*

HH Correction or change in general
FA Abandonment or withdrawal